Design of Aminobenzothiazole Inhibitors of Rho Kinases 1 and 2 by Using Protein Kinase A as a Structure Surrogate

Synthesis of a chiral dinuclear Cu(II)-benzothiazolamine complex: evidence of cuprophilic interaction in its structure and exploration of its electrochemical properties and catalytic performance

The synthesis of a chiral dinuclear [Cu(OAc)2(L1)]2 complex (A) and its analogues Cu(OAc)2(L1)2 (B), Cu(OAc)2(L1)PPh3 (C), CuBr(L1)PPh3 (D), and Cu(OAc)2(L2) (E) is described. The X-ray structure of A reveals a cuprophilic interaction (2.65 Å) and shows that L1 behaves as a monodentate ligand. The stereogenic centre in L1 aligns the NH group to form non-covalent interactions with the paddle-wheel acetate groups at variable distances (2.4-2.5 Å and 2.2-2.7 Å). Thermogravimetric analysis confirmed our hypothesis that two equivalents of L1 (B) or a combination of L1 and PPh3 (C) would disrupt the cuprophilic interaction. All complexes, except D, showed irreversible redox waves by cyclic voltammetry. Complexes C and E have lower oxidative peaks (at 10 V s-1) than complex A between +0.40 and +0.60 V. This highlights the influence of ligand(s) on the redox behaviour of Cu(II) complexes. The significance of this electrochemical behaviour was evident in the Chan-Lam (CL) coupling reaction, where 2.5 mol% of A successfully facilitated the formation of a C-N bond. This study showcased the structure, thermal stability, electrochemical properties and catalytic performance of a chiral dinuclear copper(II)-benzothiazolamine complex.

Designing of the N-ethyl-4-(pyridin-4-yl)benzamide based potent ROCK1 inhibitors using docking, molecular dynamics, and 3D-QSAR

Rho-associated kinase-1 (ROCK1) has been recognized for its pivotal role in heart diseases, different types of malignancy, and many neurological disorders. Hyperactivity of ROCK phosphorylates the protein kinase-C (PKC), which ultimately induces smooth muscle cell contraction in the vascular system. Inhibition of ROCK1 has been shown to be a promising therapy for patients with cardiovascular disease. In this study, we have conducted molecular modeling techniques such as docking, molecular dynamics (MD), and 3-Dimensional structure-activity relationship (3D-QSAR) on a series of N-ethyl-4-(pyridin-4-yl)benzamide-based compounds. Docking and MD showed critical interactions and binding affinities between ROCK1 and its inhibitors. To establish the structure-activity relationship (SAR) of the compounds, 3D-QSAR techniques such as Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA) were used. The CoMFA (q ² = 0.774, r ² = 0.965, ONC = 6, and r p r e d 2 = 0.703) and CoMSIA (q ² = 0.676, r ² = 0.949, ONC = 6, and r p r e d 2 = 0.548) both models have shown reasonable external predictive activity, and contour maps revealed favorable and unfavorable substitutions for chemical group modifications. Based on the contour maps, we have designed forty new compounds, among which, seven compounds exhibited higher predictive activity (pIC₅₀). Further, we conducted the MD study, ADME/Tox, and SA score prediction using the seven newly designed compounds. The combination of docking, MD, and 3D-QSAR studies helps to understand the coherence modification of existing molecules. Our study may provide valuable insight into the development of more potent ROCK1 inhibitors.

Recent Advances in Pain Management: Relevant Protein Kinases and Their Inhibitors

The purpose of this review is to underline the protein kinases that have been established, either in fundamental approach or clinical trials, as potential biological targets in pain management. Protein kinases are presented according to their group in the human kinome: TK (Trk, RET, EGFR, JAK, VEGFR, SFK, BCR-Abl), CMGC (p38 MAPK, MEK, ERK, JNK, ASK1, CDK, CLK2, DYRK1A, GSK3, CK2), AGC (PKA, PKB, PKC, PKMζ, PKG, ROCK), CAMK, CK1 and atypical/other protein kinases (IKK, mTOR). Examples of small molecule inhibitors of these biological targets, demonstrating an analgesic effect, are described. Altogether, this review demonstrates the fundamental role that protein kinase inhibitors could play in the development of new pain treatments.